Transdermal Cannabis Cream Significantly Reduced Diabetic Nerve Pain in Phase III Trial | Research

The takeaway

A phase III double-blind trial found a transdermal THC:CBD:CBN cannabis formulation significantly reduced diabetic neuropathy pain across all measured dimensions over 12 weeks, with only 10% experiencing mild side effects comparable to placebo.

Neurologists, endocrinologists, pain management specialists, and diabetic patients with neuropathic pain.

What the researchers found

The transdermal cannabis formulation (THC:CBD:CBN) demonstrated statistically significant reductions in NPSI-T scores across all measured pain dimensions (p<0.001) compared to placebo over 12 weeks. Only 10% of the treatment group reported mild adverse events, comparable to the placebo group.

Why it matters

Diabetic neuropathy affects millions globally and responds poorly to existing treatments. A transdermal cannabis formulation avoids the systemic side effects and psychoactivity associated with oral cannabis while delivering active compounds directly to affected areas. This is the first phase III trial of a THC:CBD:CBN transdermal for this indication.

The numbers in context

100 participants randomized. 12-week intervention. Statistically significant reductions across all NPSI-T dimensions (p<0.001). Mild adverse events in 10% of treatment group, comparable to placebo. Trial registered in Thai Clinical Trials Registry.

How the study worked

Phase III, double-blind, placebo-controlled, randomized clinical trial at Don Chan Hospital, Thailand. 100 participants with painful diabetic peripheral neuropathy of lower extremities. 12-week intervention with primary outcome measured by the Thai Neuropathic Pain Symptom Inventory (NPSI-T). GEE modeling and ANCOVA used for analysis.

What this study cannot tell us

Single-center trial in Thailand with 100 participants. 12-week duration does not assess long-term efficacy or safety. The specific THC:CBD:CBN ratios and concentrations are not detailed in the abstract. Cultural and genetic factors may affect generalizability. No active comparator (only placebo).

How to read the evidence

Phase III double-blind RCT with validated outcome measures and appropriate statistical analysis, though single-center and moderate sample size.

When this study was published

Published 2025.

The bigger picture

Transdermal delivery of cannabinoids is an emerging approach that addresses several limitations of oral and inhaled cannabis: it bypasses first-pass metabolism, provides sustained local delivery, and minimizes psychoactive effects. A positive phase III trial for diabetic neuropathy could open regulatory pathways for topical cannabis therapeutics.

Questions still open

How this transdermal formulation compares to oral gabapentin or pregabalin for diabetic neuropathy
Whether the effects persist beyond 12 weeks or require ongoing treatment

Common questions

Would this cream make you high?

Transdermal delivery is designed for local rather than systemic absorption, which typically means minimal psychoactive effects. The 10% mild adverse event rate comparable to placebo suggests the formulation does not cause significant systemic cannabinoid effects.

What makes this different from CBD creams sold in stores?

This is a pharmaceutical-grade formulation with specific THC:CBD:CBN ratios tested in a rigorous clinical trial. Over-the-counter CBD topicals are generally unregulated, vary widely in actual cannabinoid content, and have not been tested in controlled trials for neuropathic pain.

Read the original research

Efficacy and Safety of Transdermal Medical Cannabis (THC:CBD:CBN formula) to Treat Painful Diabetic Peripheral Neuropathy of Lower Extremities.

Medical cannabis and cannabinoids, 8(1), 1-14

View on PubMed ↗Publisher’s paper ↗

Citation

Seevathee, Khachornsak; Kessomboon, Pattapong; Manimmanakorn, Nuttaset; Luangphimai, Suyan; Thaneerat, Tewan; Wanaratna, Kulthanit; Plengphanich, Sirichada; Thaenkham, Thanamet; Sena, Wijitra. (2025). Efficacy and Safety of Transdermal Medical Cannabis (THC:CBD:CBN formula) to Treat Painful Diabetic Peripheral Neuropathy of Lower Extremities.. Medical cannabis and cannabinoids, 8(1), 1-14. https://doi.org/10.1159/000542511